Statement of Changes in Beneficial Ownership (4)
21 May 2020 - 9:35AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Gasmi Mehdi |
2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc.
[
ADVM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/5/2020 |
(Street)
REDWOOD CITY, CA 94063
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 5/5/2020 | | M | | 10000 | A | $4.80 | 284442 (1) | D | |
Common Stock | 5/5/2020 | | S | | 10000 (2) | D | $16.2573 (3) | 274442 | D | |
Common Stock | 5/6/2020 | | M | | 25000 | A | $4.80 | 299442 | D | |
Common Stock | 5/6/2020 | | S | | 25000 (2) | D | $20.0267 (4) | 274442 | D | |
Common Stock | 5/18/2020 | | M | | 5000 | A | $4.80 | 279442 | D | |
Common Stock | 5/18/2020 | | S | | 4700 (2) | D | $18.1115 (5) | 274742 | D | |
Common Stock | 5/18/2020 | | S | | 300 (2) | D | $19.03 (6) | 274442 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $4.80 | 5/5/2020 | | M | | | 10000 | (7) | 2/11/2026 | Common Stock | 10000 | $0.00 | 163000 | D | |
Stock Option (Right to Buy) | $4.80 | 5/6/2020 | | M | | | 25000 | (7) | 2/11/2026 | Common Stock | 25000 | $0.00 | 138000 | D | |
Stock Option (Right to Buy) | $4.80 | 5/18/2020 | | M | | | 5000 | (7) | 2/11/2026 | Common Stock | 5000 | $0.00 | 133000 | D | |
Explanation of Responses: |
(1) | The balance of shares reflected in Reporting Person's prior Form 4 was inadvertently reflected as 258,979 shares and should have been reflected as 274,298 shares. The Form 4 originally reflecting the incorrect balance, filed with the SEC on 2/14/2020, has been amended to reflect the correct end of period balance in Column 5 of Table I in that filing. |
(2) | Shares sold pursuant to a 10b5-1 plan. |
(3) | Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.15 to $16.39. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
(4) | Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.13. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
(5) | Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.63 to $18.54. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
(6) | Price reported is a weighted-average sales price. The shares were sold at prices ranging from $18.93 to $19.14. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
(7) | Fully vested and exercisable. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Gasmi Mehdi C/O ADVERUM BIOTECHNOLOGIES, INC. 800 SAGINAW DRIVE REDWOOD CITY, CA 94063 | X |
|
|
|
Signatures
|
Mehdi Gasmi, by /s/ Peter Soparkar, Attorney-in-Fact | | 5/20/2020 |
**Signature of Reporting Person | Date |
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2024 to May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From May 2023 to May 2024